Clinical Trials Worldwide
David A. Steenblock
FOUR PIONEERING STUDIES in neurological disorders include a phase 1 study at the University of Texas Health Science Center at Houston that is evaluating the safety of autologous (using the patient's own cells) bone marrow treatments in 10 children aged 5–14 years with traumatic brain injury; a phase 1/2 study at the University of Cambridge to determine the safety and effectiveness of bone marrow—derived autologous mesenchymal stem cells in multiple sclerosis; a phase 1 safety study on the use of autologous bone marrow stem cells for acute stroke, sponsored by the Federal University of Rio de Janeiro in Brazil; and a recently completed phase 1 evaluation at Inha University in Incheon, Korea, where autologous bone marrow stem cells were used to treat acute and chronic spinal cord injuries. Thirty—five patients were treated in this study, and there were no serious adverse effects. Azienda Unità Sanitaria Locale di Piacenza, in Italy, ...